Autres langues Processa Pharmaceuticals, Inc.

Actions

PCSA

US74275C4033

Recherche biotechnologique et médicale

Temps Différé Nasdaq 18:09:50 23/09/2026			Varia. 5j.	Varia. 1 janv.
1,880 ^USD	0,00%		+1,62%	-34,72%

14/08	Processa Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
29/07	Processa Pharmaceuticals, Inc. (NasdaqCM:PCSA) a acquis Vidya Therapeutics, Inc. pour environ 320 millions de dollars.	CI

Autres langues

01/09	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
14/08	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
31/07	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)
30/07	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors
29/07	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.
29/07	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors
29/07	Processa buys Vidya Therapeutics, raises $200 million for drug trials
29/07	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director
29/07	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
28/07	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding
27/07	Deals of the day-Mergers and acquisitions
08/05	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30/04	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026
20/03	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026
18/03	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
19/02	Processa Pharmaceuticals, Inc. Announces Expiration of Binding Term Sheet with Intact Therapeutics
12/01	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
05/01	Processa Pharmaceuticals, Inc. Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
05/01	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
18/12	Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
17/12	Top Midday Gainers
17/12	Processa Pharmaceuticals gives update on phase 2 study of metastatic breast cancer
17/12	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer